Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 17/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SLC27A2 | O14975 | 1/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192767 | 0.91 | ADAMTS5 (1.00) | ADAMTS5MMP12SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4984812 | 0.88 | ADAMTS5 (1.00) | ADAMTS5MMP12ADAMTS4 | |
| SCHEMBL15928242 | 0.87 | ADAMTS5 (0.76) | ADAMTS5MMP12SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6272079 | 0.86 | ADAMTS5 (0.74) | ADAMTS5MMP12SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6277083 | 0.84 | ADAMTS5 (0.72) | ADAMTS5MMP12SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6274220 | 0.84 | ADAMTS5 (0.72) | ADAMTS5MMP12SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4978954 | 0.84 | ADAMTS5 (1.00) | ADAMTS5MMP12SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4355104 | 0.84 | ADAMTS5 (0.72) | ADAMTS5MMP12SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4983832 | 0.83 | ADAMTS5 (1.00) | ADAMTS5MMP12SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6274147 | 0.81 | ADAMTS5 (0.67) | ADAMTS5MMP12SMN1; SMN2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032584-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Wyeth (US) | 2009-03-11 | — | — | EP | claimed |
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | WYETH (US) | 2008-05-29 | — | — | US | claimed |
| WO-2007146138-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WYETH (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2005092304-A2 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2005-10-06 | — | — | WO | claimed |
| US-20220202785-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| WO-2020214896-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-10-22 | — | — | WO | disclosed |
| US-9598441-B2 | Therapeutic compounds and methods | WAYNE STATE UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598441-B2 | Therapeutic compounds and methods | WAYNE STATE UNIVERSITY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2013033392-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | WYETH (US) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202785-A1 | SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS | GPR68, GPR65, GPR4 | ADAMTS5 3017/4885MMP12 1094/4885SMN1; SMN2 991/4885 |
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | ADAMTS5, ADAMTS1, TIMP3 | ADAMTS5 1/4885MMP12 26/4885SMN1; SMN2 876/4885 |
| US-20140221412-A1 | THERAPEUTIC COMPOUNDS AND METHODS | XPOT, FANCI, XPO5 | ADAMTS5 712/4885MMP12 3102/4885SMN1; SMN2 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.